Robert L. Hill, MD founded HC in 2015 after He negotiated an option to license & technology development agreement with UR Ventures, partnering with Dr. Edward Brown III’s lab, leveraging about $5 Million in grant funding to date. Dr. Hill has recently expanded the company to include Bill Huff to focus on the operational aspects of commercialization drawing on Mr. Huff’s 31 years of experience in biotech with Genentech, retirin...
Robert L. Hill, MD founded HC in 2015 after He negotiated an option to license & technology development agreement with UR Ventures, partnering with Dr. Edward Brown III’s lab, leveraging about $5 Million in grant funding to date. Dr. Hill has recently expanded the company to include Bill Huff to focus on the operational aspects of commercialization drawing on Mr. Huff’s 31 years of experience in biotech with Genentech, retiring as National Director of Reimbursement – Immunotherapy Field Products.
For cancer diagnosed at an early stage, the “elephant in the room” is the question of future deadly metastatic recurrence. Deciding which treatment is beneficial or harmful can be a flip of a coin where one side is over-treatment & the other is under-treatment. The problem HC aims to address is balancing the risks & benefits of treatment decisions at diagnosis with more accurate outcome prediction, returning patients to safety & quality of life.
Our OPTIM technology will allow a rapidly scalable business model where we take minutes to assay in our central laboratory, diagnostic pathology tissue slides, sent overnight by referring pathologists. We envision being able to provide actionable treatment guidance within a day of receiving fixed thin tissue sections prepared in the standard diagnostic workflow.
Our patent-pending optical technology uniquely focuses on the collagen extracellular matrix (soil), instead of just the cells (seeds). OPTIM is nondestructive so the same tissue slide is therefore available for further probing by genomic or other biomarkers to improve our prediction. HC is a first mover with such a rapid photonics assay with this independent prediction modality. Patent claims cover solid tumors & fibrotic diseases progression. New IP with Dr. Hill as the primary inventor, adds a method of treatment for predicting optimal neoadjuvant treatment of people diagnosed with high-risk breast cancer.
I've been privileged to collaborate with Robert on research related with areas of interest to Harmonigenic. As a layperson in medical matters, and as an Engineering research professional, it has been enlightening to be able to peer into the mind of a cancer expert and realize that rigor, creativity and systematicity are attributes not constrained to the exact sciences. I truly believe that the exceptionally novel, evidence- and statistics-based work being carried out at Harmonigenic will prove to be groundbreaking in the near future. On behalf of the Rochester Data Science Consortium team, I look forward to years of collaboration with Robert's team, and to positive and impactful outcomes in cancer treatment driven by data-based evidence.
I have been very impressed by Robert’s passion on improving the outcomes of breast cancer treatment. My colleagues and I have worked with him on a project that evaluated with the aim at improving the measurement system used by his company, Harmonigenics. The measurement system explores an innovative image-based biomarker for predicting the likelihood of breast cancer recurrence. Throughout the collaboration, Robert provided many valuable insights based on his strong background in the field of pathology. He is always excited to share his knowledge with us and open-minded to accept different perspectives and opinions. It has been a great pleasure to work with. I wish him the best for the success of his company, moreover his vision for providing more informative choices to patients for selecting the suitable treatment(s) based on their individual situations.
I have the pleasure to work with Robert and Harmonigenic from a NYS funded project on understanding the measurement capability of extracting an existing biomarker as well as exploring new image-based biomarkers that are relevant to breast cancer recurrence prediction. Throughout the collaboration, Robert has shown great enthusiasm in solving the research problem in-hand and has made significant contributions to the project: from providing the data and background, to involving in the technical discussion on the instrument and the data analysis, to sharing ideas and thoughts on improvement of the developed method. As the domain expert in medical, he helps educate us regarding to aspects to focus in our investigation and provided different perspectives that are complement to those from other team members. He actively participated in all aspects of the project and was always eager to share his knowledge on the subject matter. It has been a great experience working with him and his comp